# Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy

Source: https://onco.cc/trials/nct02444819/  
OnCo record `nct02444819` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Olmutinib in Non-small-cell lung cancer, run by Hanmi Pharmaceutical Company Limited, completed.

## Summary

Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy is a phase 2 interventional study registered as NCT02444819 by Hanmi Pharmaceutical Company Limited, with 33 participants recorded, started 2015-03 and reaching its primary completion in 2017-08. Interventions recorded: HM61713. Conditions recorded: Non Small Cell Lung Cancer.

Linked to the drug Olmutinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02444819
- Phase: 2
- Setting: A Multicenter, Single-arm, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line Anticancer Agent in NSCLC Patients With EGFR Mutation
- Sponsor: Hanmi Pharmaceutical Company Limited
- Enrolled: 33

## Sources

- ClinicalTrials.gov NCT02444819: https://clinicaltrials.gov/study/NCT02444819

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Olmutinib](https://onco.cc/drugs/olmutinib/)
- companies: [Hanmi Pharmaceutical](https://onco.cc/companies/hanmi-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct02444819.json